---
title: "Tempest gets fast track designation from FDA for amezalpat"
date: "2025-02-10 16:26:35"
summary: "Tempest Therapeutics (NASDAQ:TPST) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to amezalpat, an oral, small molecule, selective PPAR antagonist for the treatment of patients with hepatocellular carcinoma. This is the second regulatory designation granted to amezalpat. Source: Press Release"
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

* Tempest Therapeutics (NASDAQ:[TPST](https://seekingalpha.com/symbol/TPST "Tempest Therapeutics, Inc.")) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to amezalpat, an oral, small molecule, selective PPAR antagonist for the treatment of patients with hepatocellular carcinoma.
* This is the second regulatory designation granted to amezalpat.
* Source: [Press Release](https://seekingalpha.com/pr/19996547-tempest-granted-fast-track-designation-from-the-u-s-food-and-drug-administration-for)

[seekalpha](https://seekingalpha.com/news/4405555-tempest-gets-fast-track-designation-from-fda-for-amezalpat)
